LUYE PHARMA (02186) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB3.181 billion, representing a year-over-year increase of 3.46%. Profit attributable to owners of the parent company reached RMB313 million, declining 19.33% compared to the same period last year, with earnings per share of 8.32 cents.

In the Chinese market, the Group's major products maintain competitive positions across its four primary therapeutic areas: oncology, central nervous system (CNS), cardiovascular, and metabolism. According to IQVIA data, during the reporting period, oncology, metabolism, CNS, and cardiovascular-related pharmaceuticals represented the first, second, fourth, and fifth largest pharmaceutical markets in China, respectively.

The Group's main product portfolio in China includes six oncology treatments (Lipusu, Boyouno, Baitouwei, Zanbijia, Ximena, and Mimeixin), five CNS treatments (Seroquel, Ruoxinlin, Ruiketu, Meibirei, and Jinyouping), three cardiovascular treatments (Xuezhikang, Oukai, and Maitongna), and two metabolism treatments (Beixi and Boyouping).

For international markets, the Group's products are primarily positioned in the CNS therapeutic area, including Seroquel, Seroquel XR, Erzofri, Rykindo, rivastigmine single-day transdermal patch, rivastigmine multi-day transdermal patch (LY30410), rotigotine patch, fentanyl patch, and buprenorphine patch.

During the reporting period, the Group's oncology treatment revenue increased 13.5% to RMB1.295 billion. CNS treatment revenue grew 5.4% to RMB868 million. Cardiovascular system treatment revenue decreased 9.2% to RMB693 million. Metabolism treatment revenue declined 7.9% to RMB180 million.

The Group's 18 major products have established strong competitive advantages in high-prevalence disease areas globally, with market share expected to grow steadily or maintain current levels.